Progress on Dupilumab treatment for type 2 asthma in children
10.3760/cma.j.issn.1673-4408.2025.06.008
- VernacularTitle:度普利尤单抗治疗儿童2型哮喘的研究进展
- Author:
Shihe CAO
1
;
Xiaohong WANG
Author Information
1. 山西医科大学第一临床医学院，太原 030000
- Keywords:
Children;
Asthma;
Dupilumab;
Type 2 asthma
- From:
International Journal of Pediatrics
2025;52(6):395-399
- CountryChina
- Language:Chinese
-
Abstract:
In recent years，the prevalence of asthma in children has been on the rise，affecting children's physical and mental health and placing a burden on families and society. As the in-depth study of asthma phenotypes and endotypes progresses，targeted therapy for asthma has become a new treatment strategy. Dupilumab，a drug targeting IL-4 and IL-13，is used treating patients with uncontrolled moderate-to-severe type 2 asthma. It has been approved for use in children aged 6-11 years with moderate-to-severe asthma in the United States and Europe，but there are fewer reports on the treatment of type 2 asthma in children in China. Therefore，this article aims to review the research progress of Dupilumab in the treatment of type 2 asthma in children，in order to provide reference for the clinical treatment of asthma in children.
